Immunotherapy plus chemotherapy before surgery for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III lung cancer (specifically T-any N2b stage) confirmed by biopsy or tissue sample, with lymph node involvement verified by special imaging or procedures
- Your doctor has confirmed your lung cancer can be completely removed by surgery
- You are 18 years or older and in good enough health (ECOG score 0 or 1, meaning you can do most daily activities)
- Your blood counts, kidney, liver, and heart function are normal enough to safely receive treatment
- You have not received any prior cancer treatment (surgery, chemotherapy, radiation, or other drugs) for this lung cancer
- You do not have certain genetic mutations (EGFR or ALK) in your cancer cells
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests combining two immunotherapy drugs (iparomlimab and tuvonralimab) with 2 or 4 cycles of chemotherapy before surgery for patients with stage II to IIIB non-small cell lung cancer that can be removed. It aims to see if this approach helps shrink tumors and improve outcomes.
This trial tests if two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy can shrink stage III lung cancer that cannot be surgically removed, making it possible to operate. It is for people who have not had prior treatment for their lung cancer and are healthy enough for surgery.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests giving toripalimab plus another treatment (JS004) together with standard chemotherapy before lung surgery for stage IIIB–IIIC non-small cell lung cancer. It may help shrink the tumor and make surgery more effective, and it compares different treatment combinations.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Hear when a new Carcinoma, Non-Small-Cell Lung (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.